Effect of End-Stage Kidney Disease Factor on the Sedative Effects of Ciprofol

To investigate the effect of end-stage kidney disease (ESKD) factor on the sedative effects of ciprofol.

Elective kidney transplant recipients aged 18-64 years, with a body mass index (BMI) of 18.5-24.0 kg/m², Mallampati class I or II, interincisor distance ≥ 3.5 cm, and undergoing regular preoperative dialysis were enrolled. A matched control group with normal kidney function was included for comparison. The Dixon's up-and-down method was used to determine the median effective dose (ED₅₀) of ciprofol required to suppress the response to I-gel insertion. Secondary outcomes included ciprofol consumption during anesthesia maintenance, recovery time, perioperative hemodynamic changes, and adverse events. The total dosage of ciprofol used for anesthesia maintenance was recorded, and average ciprofol consumption per unit time per body weight was calculated.

No statistically significant difference were observed in the ED₅₀ or 95% confidence interval (CI) of ciprofol for suppressing the I-gel insertion response between the ESKD and control groups. Similarly, recovery time and mean ciprofol consumption during anesthesia maintenance were comparable between groups. Hemodynamic parameters remained stable throughout the perioperative period in both groups, with no significant intergroup differences. The incidence of adverse events, including hypotension, bradycardia, and respiratory depression, was also comparable between groups.

ESKD appears to have no significant effect on the sedative efficacy, anesthetic consumption, recovery profile, or safety of ciprofol.